X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Who’s the fairest of them all? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 14, 2002

    Who’s the fairest of them all?

    Valuations of the Indian pharma sector have undergone a sea change in the last couple of years. MNC pharma companies, once darling on the bourses, went out of favour with investors in mid-1999 as better growth opportunities became visible for Indian pharma majors.

    The earnings multiple in the recent past clearly suggested that investors were ready to pay a premium on companies, which had successfully reduced their dependence on domestic markets and were successful in entering the fast growing export markets.

    These companies grew at a faster clip, invested in creating intellectual property and were to a certain extent successful in monetising R&D to varying degrees. Leaders of this group are Ranbaxy and Dr Reddy’s. On the other hand, companies solely dependent on the slow growing domestic market commanded a lower valuation. For example, though Sun Pharma consistently outperformed its peers in terms of growth and profitability in the domestic market; it used to trade a discount to peers. This was largely on account of the fact that the export strategy of the company was unclear and revenue streams singular. As is evident from the charts below the out performance in case of Dr. Reddy’s and Ranbaxy is far higher than in case of Cipla and Sun Pharma.

    MNC pharma companies have been losers in terms of sales growth and consequently market capitalization over the last two years. While Indian Pharma companies market capitalization soared around 180% in the last two years, MNC market cap was down around 8%.

    Valuations across the sector are again in the process of re-alignment. On one hand, the disappointment to Dr. Reddy’s on the research front and several instances of delay in generic approvals have compelled investors to wake up and realize the need to align the risk associated with growth. Post the slide in Dr. Reddy’s; pharma stocks have remained more or less range bound the last couple of months.

    MNCs, on the other hand, have been quick in responding with most companies intensively restructuring their operations in a bid to bounce back. There was almost a ‘V’ shape recovery in the operating margins of several MNC majors. Having sensed a recovery in margins of these companies, market capitalization of these stocks are already making a partial comeback. However, the key question on the mind of investors is once things are set right and restructuring achieved, where would the growth come from?

    Investors, for the moment, seem to be at crossroads. Going forward, investors are likely to chase growth, coupled with clarity on future earnings. In the ensuing tables we have provided comparative forward valuations of Top Indian and MNC pharma companies.

    Domestic Pharma – Valuation comparison
      Dr. Reddy's Ranbaxy Cipla Sun Pharma
    CMP (Rs.) 865 885 940 578
    P/e - 02 14.4 37.5 24.6 16.3
    P/e -03 E 14.2 17.1 16.7 14.2
    Mkt Cap (Rs m) 66,173 103,103 56,400 26,993
    Mkt Cap/ Sales (x) 4.4 3.6 4.4 4.0

    To conclude, the success in the US / European generic and drug discovery space is likely to continue to be the key drivers for the Indian pharma majors. The P/E multiple of Indian pharma companies are expected to remain higher compared to their MNC peers in the short run on the back of sustained earnings growth. Further, paybacks from investments made by several domestic companies to get an exposure in the International markets are also likely to add to the optimism. However, sooner than latter, investors are going to demand a strategy post 2005 before continuing with premium valuations to these companies. On the other hand, post restructuring, visibility of growth is likely to be the key driver for the MNC pharma companies.

    MNC Pharma Companies – Valuation comparison
      Glaxo Novartis Pfizer Aventis
    CMP (Rs.) 365 238 432 365
    P/e - 02 37.6 13.2 21.3 12.6
    P/e -03 E 18.9 11.5 15.2 12.2
    Mkt Cap (Rs m) 27,010 7,616 11,880 8,395
    Mkt Cap/ Sales (x) 2.5 1.6 2.2 1.5

     

     

    Equitymaster requests your view! Post a comment on "Who’s the fairest of them all?". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS